Genedrive PLC has said it is applying for funding in a bid to gain NHS recommendation for the company’s antibiotic-linked hearing loss tests.
Updating on Monday, Genedrive said an application was in the process of being submitted for funding to help the firm gain a full, rather than conditional, recommendation for its MT-RNR1 ID kits.
These are used to screen infants for certain genetics which can be linked with long-term hearing loss if the wrong antibiotics are prescribed.
Genedrive said the application was being submitted as the NICE Early Value Assessment (EVA) scheme used to fast-track medical innovation.
This programme, which has £10 million in government backing and is supported by the National Institute for Health and Care Research.
“We are delighted that funding is to be made available for the real-world evidence generation for the NICE EVA technologies to achieve full NICE guidance,” chief executive James Cheek said.
“This gives the potential for our Genedrive MT-RNR1 ID kit to move from a conditional recommendation to a full recommendation with NICE, and accelerate adoption of the kit in the NHS."